Impax Q3 Results Linked To AstraZeneca, Amarin Wins Patent: Healthcare Biz Update

Impax Laboratories’ (NASDAQ:IPXL) third quarter results missed along the line thinks to higher-than-expected purchase costs, along with litigation expenses linked to the voluntary withdrawal of one of its generic products from the market. However, total revenue soared 21 percent, pushed primarily by improved sales of Zomig, which had been licensed from AstraZeneca Group (NYSE:AZN).

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

The new interim chief executive of Arrhythmia Research Technology (AMEX:HRT) will be Director Michael S. Gunter, after the current Chief Executive and Board member James E. Rouse stepped down effective October 26th.

Amarin Corporation (NASDAQ:AMRN) has won a patent from the United States Patent and Trademark Office that covers the pharmaceutical composition of its Vascepa capsules. The medication has already been okayed by the FDA for the treatment of high levels of triglycerides and the firm intends to list its new patent in the FDA’s Orange Book.

Don’t Miss: Who’s Winning the Weight-Loss Drug Race?